Introduction
Production of appropriate numbers of distinct blood cell types is dependent on controlling lineage commitment in the hematopoietic tissue and terminal differentiation into circulating blood cells. Transcription factors regulate the renewal of hematopoietic stem cells (HSC) and specify distinct lineages [1] [2] [3] [4] [5] [6] [7] [8] [9] . By also controlling each other's expression, transcription factors induce lineage specific gene expression and repress other differentiation routes. The differentiation of common myeloid progenitors (CMP) towards either granulocyte monocyte progenitors (GMP) or megakaryocyte erythrocyte progenitors (MEP) for example is regulated by transcription factors, among which GATA1 plays a crucial role 10;11 . However, depletion of Gata1 alone does not impair MEP differentiation or enhance myeloid output, indicating that additional factors regulate the megakaryocyte-erythroid fate 12 .
The Meis1 (myeloid ecotropoic viral insertion site 1) transcription factor gene was first described as a common viral integration site associated with tumor formation in BXH-2 mice 13 . MEIS1 overexpression together with overexpression of HOXA9 sustains leukemic stem cell potential in human acute myeloid leukemia and childhood acute lymphoblastic leukemia 14;15 .
MEIS1 is a homeobox gene of the TALE (three amino acids loop extension) family, encoded on human chromosome 2p15. The MEIS1 amino terminus contains binding domains for its interaction partners, the transcription factors HOXA9 and PBX1, followed by a homeobox DNA binding domain and carboxy-terminal transcriptional activation domains 16 . Previous studies have described alternative splicing of the MEIS1 pre-mRNA in a highly conserved manner resulting in four splice variants of which two, MEIS1B and MEIS1D, are expressed in hematopoietic cells 13;17 . MEIS1B and MEIS1D proteins differ in their carboxy-termini, resulting in a transcriptionally more active splice variant MEIS1D 18 .
MEIS1 is expressed in hematopoietic stem and progenitor cells 9;19;20 and increases during human megakaryocytic differentiation 21 . Meis1 null-mutant mice die at embryonic day 14.5 due to a poorly developed hematopoietic compartment, lack of megakaryocytes and platelets and defective vascularisation 6;7;22 . Meis1-deficient zebrafish display a lack of megakaryocytes, decreased erythrocyte levels and vascularisation defects 23 , consistent with the data from the null-mutant mice. Meis1 depletion in murine HSC using lineage-specific Cre-recombinase results in cell cycle entry and loss of quiescence 9 .
The most prominent murine models used to study Meis1 function to date rely on homologous recombination resulting in Meis1 depletion during embryogenesis. Due to the construction of these knock outs, it is also not possible to compare the function of the different Meis1 splice variants or specifically study MEIS1 in hematopoietic cells in these murine models 6;7 .
Here, we investigated for the first time the role of MEIS1 in adult human hematopoietic progenitor cells. Expression of the two MEIS1 splice variants was modulated in sorted hematopoietic stem and progenitor cell subsets using lentiviral knockdown or overexpression of MEIS1 fused to GFP, an approach that had been described before 24 enabling us to delineate the effects of MEIS1 on specific stages of lineage commitment. Furthermore, using transcriptional profiling on MEIS1 over expressing CD34 + hematopoietic stem and progenitor cells, we generated an overview of the transcriptional changes following MEIS1 expression.
Methods
Please see supplemental methods for additional information.
Human CD34 + cells
Mobilized peripheral blood (MPB) and cord blood (CB) cells were obtained .
MEIS1
mRNA was present in all subfractions, with MEIS1D 4-fold higher expressed than MEIS1B (Fig. 1B) + cells were enriched for hematopoietic stem cells (HSC), common myeloid progenitors (CMP), granulocyte-monocyte protenitors (GMP) and megakaryocyte-erythroid progenitors (MEP) using flow cytometry followed by RNA isolation. cDNA was synthesized and qRT-PCR was performed with specific primers for MEIS1B or MEIS1D. Gene expression was calculated relative to the -glucoronidase (GUS) reference gene using the deltaCT method. Experiments were performed in triplicate with CD34 + cells from three independent donors, statistical analysis was performed using an unpaired two-tailed Student t-test. (C) Western Blot analysis of MEIS1 expression in CB-and MPB-derived CD34 + cells directly after isolation (day 0) and after 7 days in culture promoting megakaryopoiesis with TPO and IL-1 . RhoGDI was used to show equal protein loading. A representative image is shown from three biologically independent experiments. (D) MEIS1B and MEIS1D mRNA during megakaryopoiesis. RNA samples were taken from MPB-derived CD34 + cells, which were then cultured towards megakaryocytes. Additional RNA samples were taken at day seven of megakaryocyte culture from sorted CD41 + and CD41 -fractions. CD41 + cells were cultured further until day 14 and a last RNA sample was taken. cDNA was generated and MEIS1 expression was determined using qRT-PCR. Data from three biologically independent experiments is shown. * indicates p < 0.05, ** indicates p < 0.01 with sh68 (152 ± 38) and by 30% with sh72 (145 ± 39) ( Fig 2G) and colony size compared to shc002 (174 ± 32) ( Fig 2H) . These results suggest that MEIS1 expression in hematopoietic progenitors, especially MEIS1D, , induces a MEP-fate in hematopoietic stem and progenitor cells.
MEIS1 induces erythroid commitment in myeloid progenitor cells
To determine at which level of hematopoietic commitment the MEIS1 variants exert their effects, MPB-derived CD34 + cells were sorted into HSC, CMP and + cells. 2,500 transduced, GFP-positive cells were seeded into semisolid medium. After two weeks, colonies were fixed, stained for CD41 expression (red) and Evans Blue as counterstain (blue) and CD41 + colonies were counted. Representative images were taken with a brightfield microscope using a 10x magnification. All experiments were performed in triplicate using cells from three independent donors, statistical analysis was carried out using an unpaired twotailed Student t-test. * indicates p < 0.05, ** indicates p < 0.01. GMP (Fig. 3A) , transduced with MEIS1B or MEIS1D overexpression vectors, sorted for GFP expression and seeded into semisolid medium. Neither MEIS1B nor MEIS1D overexpression significantly changed the differentiation potential of the HSC-enriched fraction (Fig. 3B) . Expression of either splice variant in the CMP caused a 2-fold increase in erythroid colonies, accompanied by a significant decrease in CFU-GM (Fig. 3C ) reflectig the phenotype of total CD34 + cells after MEIS1 overexpression (Fig. 2C) .
Strikingly, expression of the MEIS1 splice variants enabled the formation of erythroid colonies in the GMP fraction, a progenitor subset committed to differentiate into granulocytic-monocytic cells. The increase in erythroid colonies was accompanied by a significant reduction in CFU-GM (Fig. 3D + cells were sorted into stem and progenitor subsets, transduced with MEIS1 overexpression constructs, and 48 hours after transduction sorted again for GFP expression. 1,000 GFP-positive cells per condition were seeded into semisolid medium, and colonies were counted after two weeks of incubation. Experiments were performed in triplicate with CD34 + cells from three independent donors, statistical analysis was carried out using an unpaired two-tailed Student t-test. * indicates p < 0.05, ** indicates p < 0.01.
MEIS1 positively regulates erythroid determination
To further examine the role of MEIS1 in erythroid commitment and differentiation, transduced CD34 + cells were grown in liquid culture supporting erythroid proliferation and differentiation.
A 2.3-fold increase in cellular yield was observed upon overexpression of MEIS1B and a 2.2-fold increase was found with MEIS1D overexpression compared to empty vector controls (Fig. 4A) . While cell numbers increased with MEIS1 expression, glycophorin A (CD235a) expression was the same for MEIS1B or MEIS1D expressing cells as well as for empty vector cells ( (Fig. 4C ).
Also, a trend towards increased CD235a expression was detected (Fig. 4C ), but differences did not reach significance. Silencing MEIS1 did not affect the amount of cells (Fig. 4D ), consistent with a physiological downregulation of MEIS1B and MEIS1D during physiological erythropoiesis (Fig. 4E ). Together these findings indicate that MEIS1 expression is crucial to establish an erythroid fate in hematopoietic progenitor cells but is not needed for erythoid differentiation.
MEIS1 expression induces a megakaryocyte-erythroid progenitor fate
Elevated MEIS1B or MEIS1D expression increased erythroid colony formation from CMP and GMP, suggesting that MEIS1 induces a MEP gene expression (Fig. S4 B, -D) , and this correlation was significant for MEIS1B (Fig. S4 ). Among the positively correlated genes, the erythroid markers KLF1, HBB and RHAG were detected (Table S3) On the other hand, even though results between our study and the findings from Cai et al differ, in both cases a clear effect of MEIS1 on cell proliferation was detected. The effect of MEIS1 on proliferation has also been reported earlier in the context of retina development 24 indicating a robust and conserved role for MEIS1 in proliferation that seems to be tissue-independent.
We further investigated the dynamics of the observed bias towards the MEP fate using expression profiling of MEIS1 over expressing CD34 + cells. . However, we also found genes that were slightly increased in expression upon MEIS1 overexpression in GMPs, such as the monocyte-specific gene CD68. Instead, the clear induction of erythroidmegakaryocyte specific genes strongly suggests that MEIS1 overexpression directly promotes a MEP fate.
Two MEIS1 splice variants, MEIS1B and MEIS1D, are expressed in hematopoietic stem and progenitor cells and their expression decreases from the most immature stem cells to more committed progenitors 13;17 .
Structurally, the two splice variants both contain the N-terminal PBX/HOXinteracting domain, a central DNA-binding homeodomain, and 2 C-terminal transactivation (TA) domains, but MEIS1B has an additional TA domain which regulates the transcriptional activity of MEIS1 16;18 . Upon trimerization with PBX1 and HOXA9, MEIS1 maintains the transcriptional activity of the complex by inhibiting nuclear export and promoting nuclear import 34;35 . By separate overexpression of the splice variants, we showed that both induce the same phenotype, a skewing of CMP and GMP towards a MEP fate. Expression profiling further revealed that both splice variants control expression of many common transcripts, strongly indicating overlapping functions. However, in most experiments we observed a stronger phenotype upon overexpression of MEIS1D, suggesting more efficient regulation of gene expression by MEIS1D.
Earlier studies also investigated the role of Meis1 splice variants, using a model of primitive hematopoiesis. In this setting, it was found that expressing Meis1b, which is equivalent to MEIS1D in our study, showed a significant skewing of MEPs towards the megakaryocytic lineage 30 . This further underlines the stronger transcriptional activity of MEIS1D.
While it has been shown that Meis1 depletion in murine HSCs results in loss of quiescence and increased cell cycle entry We cloned in a cassette containing a U6 promoter with the appropriate short hairpin RNA (shRNA) sequence. The shRNA sequence used against MEIS1 exon 7 (sh72) was 5'-CCCTC TTGGAACAGAGATCAT-3', against the 3'UTR of MEIS1 (sh68) was 5'-GCCGTGTGTTTAGAAGCCTAA-3' and as a nontargeting shRNA control (shc002) 5'-CAACAAGATGAAGAGCACCAA-3' was used. All vectors were verified by sequencing.
Lentivirus production
Lentiviral particles were produced in 293T cells using the third generation Gene expression is shown relative to empty vector after overexpression of either MEIS1B or MEIS1D. 
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